Once-daily oral deferasirox for the treatment of transfusional iron overload

Expert Review of Clinical Pharmacology

Volumn 1, Issue 2, 2008, Pages 231-240

  Galanello, Renzo ^a   Origa, Raffaella ^b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b NONE

Author keywords

Deferasirox; Exjade ; Iron chelation; Iron overload; Once daily; Oral

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; CREATININE; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; DEFEROXAMINE MESYLATE; FERRITIN; IRON CHELATING AGENT;

ABDOMINAL PAIN; AGRANULOCYTOSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BETA THALASSEMIA; BINDING AFFINITY; BLOOD TRANSFUSION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CYTOPENIA; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG MONITORING; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FERRITIN BLOOD LEVEL; GASTROINTESTINAL TOXICITY; HUMAN; IRON CHELATION; IRON OVERLOAD; KIDNEY FAILURE; LIVER FAILURE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; NONHUMAN; PATIENT COMPLIANCE; PATIENT MONITORING; PATIENT SAFETY; POSTMARKETING SURVEILLANCE; PRESCRIPTION; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; VOMITING;

EID: 49249111541     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/17512433.1.2.231     Document Type: Article

References (42)

1. Bowen D, Culligan D, Jowitt S et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br. J. Haematol. 120(2), 187-200 (2003).
2. Adams RJ, McKie VC, Hsu L et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N. Engl. J. Med. 339 (1), 5-11 (1998).
3. Pootrakul P, Kitcharoen K, Yansukon P et al. The effect of erythroid hyperplasia on iron balance. Blood 71(4), 1124-1129 (1988).
4. Kruszewski M, The role of labile iron pool in cardiovascular diseases. Acta Biochim. Pol. 51(2), 471-480 (2004).
5. Borgna-Pignatti C, Cappellini MD, De Stefano P et al. Survival and complications in thalassemia. Ann. NY Acad. Sci. 1054, 40-47 (2005).
6. Brittenham GM, Griffith PM, Nienhuis AW et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia, major. N. Engl. J. Med. 331(9), 567-573 (1994).
7. Gabutti V, Piga A. Results of long-term iron-chelating therapy. Acta Haematol. 95(1), 26-36 (1996).
8. Ferriprox. Product information. Apotex, Ontario, Canada (1999).
9. Ceci A, Baiardi P, Felisi M et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br. J. Haematol. 118 (1), 330-336 (2002).
10. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 102(5), 1583-1587 (2003).
11. Tanner MA, Galanello R, Dessi C et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 115(4), 1876-1884 (2007).
12. Steinhauser S, Heinz U, Bartholoma M et al. Complex formation of ICL670 and related ligands with Fe III and Fe II. Eur. J. Inorg. Chem. 21, 4177-4192 (2004).
13. Nick H, Wong A, Acklin P et al. ICL670A: preclinical profile. Adv. Exp. Med. Biol. 509, 185-203 (2002).
14. Nick H, Acklin P, Lattmann R et al. Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr. Med. Chem. 10(12), 1065-1076 (2003).
15. Galanello R, Piga A, Alberti D et al. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to β-thalassemia. J. Clin. Pharmacol. 43(6), 565-572 (2003).
16. Nisbet-Brown E, Olivieri NF, Giardina PJ et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 361(9369), 1597-1602 (2003).
17. Porter JB, Abeysinghe RD, Marshall L, Hider RC, Singh S. Kinetics of removal and reappearance of non-transferria-bound plasma iron with deferoxamine therapy. Blood 88 (2), 705-713 (1996).
18. Galanello R, Piga A, Forni G-L et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in paediatric patients with β-thalassaemia major. Haematologica 91(10), 1343-1351 (2006).
19. Piga A, Galanello R, Forni G-L et al. Randomized Phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 91(7), 873-880 (2006).
20. Cappellini MD, Cohen A, Piga A et al. A Phase III study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia. Blood 107(9), 3455-3462 (2006).
21. Vichinsky E, Onyekwere O, Porter J et al. A randomized comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J. Haematol 136(3), 501-508 (2007).
22. Porter JB, Galanello R, Saglio G et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-year prospective study. Eur. J. Haematol. (2007) (Epub ahead of print).
23. Porter J, Borgna-Pignatti C, Baccarani M et al. Iron chelation efficiency of deferasirox (Exjade®, ICL670) in patients with transfusional hemosiderosis. Blood 106(11), (2005) (Abstract 2690).
24. Piga A, Bejaoui M, Kilinc Y et al. Long-term treatment with the once-daily oral iron chelator deferasirox (Exjade®, ICL670) is effective and generally well tolerated in pediatric patients. Blood 108(11), (2006) (Abstract 1781).
25. Porter JB, Cohen A, Agaoglu L et al. Long-term effects of deferasirox (Exjade®, ICL670) on serum ferritin: outcome of dose adjustments in achieving maintenance or reduction in body iron stores. Blood 108 (11), 1769 (2006).
26. Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in {β}-thalassemnia major. Blood 111(2), 583-587(2007).
27. Greenberg P, Dine G, Ganser A et al. Deferasirox (Exjade®, ICL670) demonstrates dose-related effects on body iron levels related to transfusional iron intake in transfusion-dependent anemia. Blood 106(11), (2005) (Abstract 2694).
28. Tchernia G, Vichinsky E, Jeng M et al. The once-daily oral iron chelator ICL670 is well tolerated and effective in treating transfusional iron overload in Diamond-Blackfan anaemia patients. Haematologica 90(Suppl. 2), 192 (2005).
29. Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P. LPI-labile plasma iron in iron overload. Best Pract. Res. Clin. Haematol. 18(2), 277-287 (2005).
30. Daar S, Taher A. Pathare A et al. Sustained protection fiom labile plasma iron (LPI) with the once-daily, oral iron chelator deferasirox (Exjade®, ICL670) in iron-overloaded β-thalassemia patients. Blood 108(11), (2006) (Abstract 1773).
31. Glickstein H, El RB, Link G et al. Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood 108(9), 3195-3203(2006).
32. Wood JC, Otto-Duessel M, Gonzales I et al. Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil. Translational Res. 148(5), 272-280 (2006).
33. Eleftheriou P, Tanner M, Pennell D, Porter JB. Response of myocardial T2* to oral deferasirox monotherapy for 1 year in 29 patients with transfusion-dependent anaemias; a subgroup analysis. Haematologica 91(Suppl. 1), (2006) (Abstract 999).
34. Vichinsky E, Fischer R, Pakbaz Z et al. Satisfaction and convenience of chelation therapy in patients with sickle cell disease (SCD): comparison between deferasirox (Exjade®, ICL670) and deferoxamine (DFO). Blood 106(11), (2005) (Abstract 2334).
35. Cappellini MD, Bejaoui M, Agaoglu L et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with β-thalassemia. Clin. Ther. 29(5), 909-917(2007).
36. Cappellini MD, Giardina P, Porter J et al. Long-term, safety and tolerability of the once-daily, oral iron chelator deferasirox (Exjade®, ICL670) in patients with transfusional iron overload. Blood 108(11), 1768 (2006).
37. Bennett W, Ponticelli C, Piga A et al. Summary of long-term renal safety data in transfused patients with secondary iron overload receiving deferasirox (Exjade®, ICL670). Blood 108(11), (2006) (Abstract 3816).
38. Origa R, Galanello R, Ganz T et al. Liver iron concentrations and urinary hepcidin in β-thalassemia. Haematologica 92(5), 583-588 (2007).
39. Rassi F, Ismaeel H, Inati A et al. High degree of iron burden in transfusion-naive thalassemia intermedia patients. Haematologica 92 (Suppl. 1), 301 (2007).
40. Fleming RE, Britton RS, Waheed A, Sly WS, Bacon BR. Pathophysiology of hereditary hemochromatosis. Semin. Liver Dis. 25(4), 411-419 (2005).
41. Mavrogeni S, Gotsis ED, Berdousi E et al. Myocardial and hepatic T2* magnetic resonance evaluation in ex-thalassemic patients after bone-marrow transplantation. Int. J. Cardiovasc. Imaging 23(6), 739-745 (2007).
42. Jastaniah W, Harmatz P, Pakbaz Z et al. Transfusional iron burden and liver toxicity after bone marrow transplantation for acute myelogenous leukemia and hemoglobinopathies. Pediatr. Blood Cancer 50(2), 319-324 (2008).